A noninvasive method for administering monoclonal antibodies reliably and reproducibly to central nervous system (CNS) targets remains a significant unmet need. Researchers in Switzerland have reported making headway in bypassing the blood-brain barrier through the intranasal delivery of full-length antibodies in rodent models. They show this delivery route leads to rapid transfer of significant amounts of a mouse antibody targeted against Nogo-A, a membrane protein that inhibits growth of neurites in the brain and spinal cord.